Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 14

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 14
---
 expect our expenses to increase in connection with our ongoing activities. Our plan, which includes pre-clinical and clinical efforts, conducting research, furthering development, continuing current and future pre-clinical and clinical trials and, eventually, commercialization of our novel therapeutics technology will involve substantial costs. If we obtain regulatory approval for any of our product candidates, we expect to incur additional significant commercialization expenses related to regulatory requirements, product manufacturing, marketing, sales and distribution.

Furthermore, we expect to incur additional costs associated with operating as an SEC reporting public company. We may also encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may increase our capital needs and/or cause us to spend our cash resources faster than we expect.

Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never achieve, we expect to finance our cash needs primarily through public or private equity offerings, debt financings or through the establishment of possible strategic alliances.

Between 2020 and 2023, we raised aggregate gross proceeds of $8.15 million, from sales of our equity and equity linked securities. Nonetheless, we will need to obtain substantial additional funding for the further development and commercialization of our product candidates and to continue our operations. The actual amount of funds that we will need will be determined by many factors, some of which are beyond our control. These factors include:

| ● | The                                                                                            
 progress and breadth of pre-clinical testing and the size or complexity of our clinical trials 
 and drug delivery programs, all of which directly influence cost;                              |

| ● | Higher                                                                                           
 than expected costs involved in complying with the regulatory process to get our drug candidates 
 approved, including the number, size, and timing of necessary clinical trials and costs and      
 review of existing clinical and pre-clinical information;                                        |

| ● | Higher                                                                                     
 than expected costs involved in patenting our technologies and defending them and pursuing 
 our overall intellectual property strategy.                                                |

<div align='center'>8</div>

| ● | Changes                                                                                         
 in our existing research and development relationships and our ability to efficiently negotiate 
 and enter into new collaboration and partnership agreements;                                    |

| ● | Our                                                                                      
 ability to establish and maintain current and new research and development and licensing 
 arrangements and terminations of our existing collaboration and licensing arrangements.  |

| ● | Faster                                                                                         
 or slower than expected rate of progress and changes in the scope and the cost of our research 
 and development and clinical trial activities.